Company intelligence / Profile preview
Regend Therapeutics
Chinaen.regend.cn ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
The phase I clinical trial of lung progenitor cell product REGEND001 for chronic obstructive pulmonary disease was elected as one of the top three annual progresses by the European Respiratory Society in 2023. REGEND001 has shown improvement in gas transfer capacity, lung capacity, life quality, functional exercise capacity, and other lung function measures in patients with various chronic pulmonary diseases. It has successfully repaired damaged lung structures, diminished emphysema lesions in COPD, reduced broncho-arterial ratio and inflammatory areas in bronchiectasis, and resolved fibrotic tissues in idiopathic pulmonary fibrosis.[1]
- Therapeutic areas
- OncologyPulmonologyImmunologyNephrology
- Modalities
- Cell therapyGene therapyTherapeutic vaccinecircRNA vaccine
- Industry
- Biotech
02
Drug pipeline
9 assets8 more assets in the full pipeline.
Beyond the preview
Go deeper on Regend Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Regend Therapeutics.